The clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis.
CONCLUSIONS: Our results confirm the prognostic significance of PD-L1 expression in thyroid cancer patients. PD-L1 expression has the potential to be implemented as a prognostic biomarker used to guide clinicians in identifying patients with more aggressive cancers, and for the selection of individuals that would derive durable clinical benefit from anti-PD-1/PD-L1 immunotherapy. Prospective clinical trials will be useful to support these findings.
PMID: 29455638 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Endocrinology | Immunotherapy | Study | Thyroid | Thyroid Cancer | Thyroiditis